Free Trial
→ NNVC FDA = New Momentum Wave! (From Equiscreen) (Ad)tc pixel Free IBRX Stock Alerts

ImmunityBio (IBRX) Financials

ImmunityBio logo
$8.22 +0.07 (+0.80%)
As of 03:07 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for ImmunityBio

Annual Income Statements for ImmunityBio

This table shows ImmunityBio's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -237 -121 -96 -96 -158 -222 -347 -417 -583 -414 -351
Consolidated Net Income / (Loss)		 -237 -121 -96 -96 -160 -224 -350 -417 -584 -414 -351
Net Income / (Loss) Continuing Operations		 -237 -121 -96 -96 -160 -224 -350 -417 -584 -414 -351
Total Pre-Tax Income 		-237 -121 -97 -97 -160 -226 -350 -417 -584 -414 -352
Total Operating Income		 -239 -125 -99 -98 -156 -221 -330 -351 -362 -344 -256
Total Gross Profit		 0.24 0.04 0.05 0.05 2.20 0.61 0.93 0.24 0.62 15 113
Total Revenue		 0.24 0.04 0.05 0.05 2.20 0.61 0.93 0.24 0.62 15 113
Operating Revenue		 0.24 0.04 0.05 0.05 2.20 0.61 0.93 0.24 0.62 15 113
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.75
Operating Cost of Revenue		 - - - - - - - 0.00 0.00 0.00 0.75
Total Operating Expenses		 239 125 99 98 158 221 331 352 363 359 369
Selling, General & Admin Expense		 228 95 57 43 46 71 135 103 130 169 150
Research & Development Expense		 11 29 42 56 112 140 196 248 232 190 219
Impairment Charge		 - - - - 0.00 11 0.00 0.68 0.89 0.00 0.00
Total Other Income / (Expense), net		 1.70 3.12 2.20 1.66 -4.01 -5.15 -20 -66 -222 -69 -96
Interest Expense		 0.00 0.07 0.62 0.43 5.92 9.07 15 64 129 154 113
Interest & Investment Income		 2.99 3.10 2.67 1.86 2.44 2.44 -4.90 -15 -6.42 7.98 6.41
Other Income / (Expense), net		 -1.29 0.09 0.16 0.24 -0.53 1.49 0.19 13 -86 77 11
Income Tax Expense		 -0.30 -0.57 -0.49 -0.50 -0.11 -1.85 0.01 0.03 -0.04 0.00 -0.14
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - -2.38 -2.34 -3.06 -0.75 -0.66 -0.08 -0.07
Basic Earnings per Share		 ($3.31) ($1.47) ($1.20) ($1.22) ($0.43) ($0.59) ($0.89) ($1.04) ($1.15) ($0.59) ($0.38)
Weighted Average Basic Shares Outstanding		 71.52M 81.98M 80.58M 79.13M 366.32M 377.07M 389.23M 399.90M 508.64M 697.31M 919.86M
Diluted Earnings per Share		 ($3.31) ($1.47) ($1.20) ($1.22) ($0.43) ($0.59) ($0.89) ($1.04) ($1.15) ($0.62) ($0.38)
Weighted Average Diluted Shares Outstanding		 71.52M 81.98M 80.58M 79.13M 366.32M 377.07M 389.23M 399.90M 508.64M 700.44M 919.86M
Weighted Average Basic & Diluted Shares Outstanding		 71.52M 81.98M 80.58M 79.13M 94.21M 103.55M 397.91M 435.84M 673.95M 853.44M 1.03B

Quarterly Income Statements for ImmunityBio

This table shows ImmunityBio's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -96 -233 -134 -269 -171 -59 -130 -185 -135 98 -633
Consolidated Net Income / (Loss)		 -96 -233 -134 -269 -172 -59 -130 -185 -135 98 -633
Net Income / (Loss) Continuing Operations		 -96 -233 -134 -253 -178 -59 -130 -211 -164 154 -633
Total Pre-Tax Income 		-96 -233 -134 -269 -172 -59 -130 -185 -135 98 -633
Total Operating Income		 -80 -85 -95 -199 -161 -69 -64 -143 -111 62 -70
Total Gross Profit		 0.08 0.14 0.04 0.00 6.11 7.55 16 -0.27 32 65 44
Total Revenue		 0.08 0.14 0.04 0.00 6.11 7.55 17 0.00 32 65 44
Operating Revenue		 0.08 0.14 0.04 - 6.11 7.55 17 - 32 - 44
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.06 0.27 0.35 0.07 0.24
Operating Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.06 0.27 0.35 0.07 0.24
Total Operating Expenses		 80 86 95 201 173 77 81 195 175 -83 114
Selling, General & Admin Expense		 32 33 42 99 72 42 33 85 73 -40 46
Research & Development Expense		 48 52 53 102 101 35 48 110 102 -43 68
Total Other Income / (Expense), net		 -16 -148 -39 -52 -11 10 -65 -15 -21 6.14 -563
Interest Expense		 35 32 37 60 80 38 29 31 55 -2.47 28
Interest & Investment Income		 -1.22 0.48 3.10 3.78 3.60 1.19 0.89 2.31 4.13 -0.92 2.31
Other Income / (Expense), net		 21 -116 -4.55 3.75 66 47 -37 13 30 4.60 -537
Income Tax Expense		 0.00 -0.04 0.00 0.00 0.00 - -0.23 0.54 -0.04 -0.40 0.00
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.06 -0.02 -0.02 -0.04 -0.05 -0.02 -0.02 -0.04 -0.04 0.03 -0.02
Basic Earnings per Share		 ($0.19) ($0.37) ($0.20) ($0.20) ($0.12) ($0.07) ($0.15) ($0.10) ($0.07) ($0.06) ($0.62)
Weighted Average Basic Shares Outstanding		 498.38M 508.64M 672.83M 686.94M 695.90M 697.31M 853.16M 888.22M 946.60M 919.86M 1.03B
Diluted Earnings per Share		 ($0.19) ($0.37) ($0.20) ($0.20) ($0.14) ($0.08) ($0.15) ($0.10) ($0.07) ($0.06) ($0.62)
Weighted Average Diluted Shares Outstanding		 498.38M 508.64M 672.83M 686.94M 697.96M 700.44M 853.16M 888.22M 946.60M 919.86M 1.03B
Weighted Average Basic & Diluted Shares Outstanding		 667.71M 673.95M 691.57M 696.53M 696.83M 853.44M 882.62M 945.25M 984.97M 1.03B 1.05B

Annual Cash Flow Statements for ImmunityBio

This table details how cash moves in and out of ImmunityBio's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 117 -168 16 -7.05 -19 -41 146 -76 161 -122 -54
Net Cash From Operating Activities		 -25 -39 -49 -63 -152 -172 -274 -338 -367 -391 -305
Net Cash From Continuing Operating Activities		 -25 -39 -49 -63 -152 -172 -274 -338 -367 -391 -305
Net Income / (Loss) Continuing Operations		 -237 -121 -96 -96 -160 -224 -350 -417 -584 -414 -351
Consolidated Net Income / (Loss)		 -237 -121 -96 -96 -160 -224 -350 -417 -584 -414 -351
Depreciation Expense		 1.47 3.61 5.57 9.56 14 13 14 18 19 18 16
Amortization Expense		 0.04 2.18 1.60 0.46 - 0.79 0.47 18 42 21 -2.75
Non-Cash Adjustments To Reconcile Net Income		 210 73 38 23 6.38 23 69 50 149 -1.64 81
Changes in Operating Assets and Liabilities, net		 -0.02 3.27 2.58 0.05 -12 16 -8.18 -6.51 7.68 -15 -47
Net Cash From Investing Activities		 -175 -114 100 57 19 -20 -85 27 -30 -12 -150
Net Cash From Continuing Investing Activities		 -175 -114 100 57 19 -20 -85 27 -30 -12 -150
Purchase of Property, Plant & Equipment		 -2.24 -6.56 -35 -13 -4.29 -1.67 -34 -78 -31 -6.89 -4.25
Acquisitions		 -1.82 - - - - 0.00 0.00 -22 0.00 -1.00 0.00
Purchase of Investments		 -198 -273 -111 -95 -87 -92 -142 -34 -10 -141 -241
Sale and/or Maturity of Investments		 27 166 254 165 112 74 70 162 10 137 96
Net Cash From Financing Activities		 317 -16 -35 -0.77 114 151 505 234 558 282 400
Net Cash From Continuing Financing Activities		 317 -16 -35 -0.77 114 151 505 234 558 282 400
Repayment of Debt		 -0.13 -0.03 -20 -0.48 48 - 339 174 259 0.00 -1.13
Issuance of Debt		 - - - - - 64 0.00 0.00 193 97 2.88
Issuance of Common Equity		 316 - 1.22 0.00 30 86 166 60 110 111 401
Other Financing Activities, net		 5.81 0.32 -1.04 -0.07 39 0.67 0.98 -0.94 -3.23 73 -2.07
Effect of Exchange Rate Changes		 - - - - -0.02 -0.03 0.05 0.28 -0.29 -0.02 0.02
Cash Interest Paid		 0.00 0.07 0.67 0.48 0.02 0.04 2.11 35 77 92 71
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.00 0.01 0.02 0.00

Quarterly Cash Flow Statements for ImmunityBio

This table details how cash moves in and out of ImmunityBio's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 134 87 -132 -2.97 -18 32 -83 77 -77 28 117
Net Cash From Operating Activities		 -87 -115 -107 -100 -99 -85 -86 -80 -69 -70 -75
Net Cash From Continuing Operating Activities		 -87 -116 -107 -99 -100 -85 -86 -80 -69 -70 -75
Net Income / (Loss) Continuing Operations		 -96 -233 -134 -135 -86 -59 -130 -93 -67 -62 -633
Consolidated Net Income / (Loss)		 -96 -233 -134 -135 -86 -59 -130 -93 -67 -62 -633
Depreciation Expense		 4.59 4.56 4.56 4.41 4.46 4.14 3.83 3.88 3.95 3.87 4.38
Amortization Expense		 11 7.00 5.06 5.44 5.62 4.98 -0.05 -0.01 -0.98 -1.70 -1.53
Non-Cash Adjustments To Reconcile Net Income		 -0.27 132 20 21 -18 -26 60 12 6.40 1.84 554
Changes in Operating Assets and Liabilities, net		 -7.52 -26 -2.76 4.27 -6.55 -9.57 -20 -3.49 -11 -12 0.88
Net Cash From Investing Activities		 -16 2.25 -36 -51 65 9.83 4.13 -16 -181 44 -32
Net Cash From Continuing Investing Activities		 -16 2.25 -36 -51 65 9.83 4.13 -16 -181 44 -32
Purchase of Property, Plant & Equipment		 -5.68 -7.96 -1.26 -0.72 -2.79 -2.11 -1.12 -1.08 -0.74 -1.31 -1.79
Purchase of Investments		 -9.96 -0.17 -48 -86 -0.75 -6.09 -0.10 -15 -181 -46 -149
Sale and/or Maturity of Investments		 - 10 14 35 70 18 5.35 - - 90 119
Net Cash From Financing Activities		 238 201 10 149 16 107 -0.98 173 174 55 224
Net Cash From Continuing Financing Activities		 238 201 10 149 16 107 -0.98 173 174 55 224
Repayment of Debt		 199 - - - - - 0.00 - - - -0.87
Issuance of Debt		 - 193 - 97 - - 0.00 - - 2.88 177
Other Financing Activities, net		 -1.45 -1.58 10 48 16 -0.80 -0.98 -0.33 -0.16 -0.60 48
Cash Interest Paid		 7.38 44 24 24 24 21 16 19 18 19 20

Annual Balance Sheets for ImmunityBio

This table presents ImmunityBio's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 367 317 250 182 143 221 469 362 504 383 502
Total Current Assets		 298 205 132 89 56 112 334 141 294 185 315
Cash & Equivalents		 176 8.08 24 17 16 35 181 105 265 143 88
Short-Term Investments		 118 191 104 57 36 61 136 2.54 1.01 6.38 154
Accounts Receivable		 0.22 1.09 0.15 - - 2.00 1.33 1.89 2.02 2.65 43
Inventories, net		 - - - - - - - - 0.00 8.27 0.91
Prepaid Expenses		 3.11 5.14 4.15 14 4.11 14 16 32 26 24 29
Plant, Property, & Equipment, net		 5.52 19 77 77 61 73 83 144 146 137 114
Total Noncurrent Assets		 64 93 41 16 27 37 52 78 64 61 73
Long-Term Investments		 55 88 30 5.70 1.50 0.95 0.82 0.84 0.89 - 14
Noncurrent Note & Lease Receivables		 - - - - - 6.13 6.38 6.63 6.88 7.13 7.38
Other Noncurrent Operating Assets		 1.36 0.79 8.83 10 25 29 43 51 39 38 51
Total Liabilities & Shareholders' Equity		 367 317 250 182 143 221 469 362 504 383 502
Total Liabilities		 11 24 32 36 22 340 713 812 1,090 871 1,001
Total Current Liabilities		 6.15 13 21 27 12 68 369 501 58 55 62
Accounts Payable		 3.44 5.80 8.23 4.49 2.24 63 67 66 53 47 54
Other Current Liabilities		 0.14 0.89 1.37 1.67 3.98 5.02 3.01 2.65 5.24 7.47 7.54
Total Noncurrent Liabilities		 4.71 12 11 8.68 11 272 344 311 1,032 816 940
Long-Term Debt		 - - - - - 254 306 241 837 746 802
Other Noncurrent Operating Liabilities		 0.00 2.27 2.00 5.95 11 17 37 70 195 70 138
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 356 293 219 146 121 -118 -244 -450 -586 -488 -500
Total Preferred & Common Equity		 356 293 219 146 121 -120 -242 -447 -587 -489 -500
Total Common Equity		 356 293 219 146 121 -120 -242 -447 -587 -489 -500
Common Stock		 607 681 718 741 783 1,495 1,720 1,931 2,375 2,885 3,197
Retained Earnings		 -250 -387 -499 -595 -662 -1,615 -1,962 -2,378 -2,962 -3,375 -3,727
Accumulated Other Comprehensive Income / (Loss)		 -0.19 -0.28 -0.38 -0.27 -0.11 0.12 0.00 0.18 0.01 1.20 29
Noncontrolling Interest		 - - - - - 1.32 -1.74 -2.49 1.05 0.97 0.90

Quarterly Balance Sheets for ImmunityBio

This table presents ImmunityBio's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 353 343 291 432 401 444 365 304 402 519 647
Total Current Assets		 143 113 67 215 196 243 163 109 208 329 453
Cash & Equivalents		 104 88 44 178 133 130 112 61 138 60 205
Short-Term Investments		 6.90 2.79 2.45 12 37 88 18 0.93 16 198 176
Accounts Receivable		 1.49 1.46 2.03 2.33 2.14 2.06 4.90 17 22 32 43
Inventories, net		 - - - - - 1.81 1.96 8.44 6.64 6.70 0.55
Prepaid Expenses		 31 21 19 23 23 21 26 22 26 33 28
Plant, Property, & Equipment, net		 130 154 151 152 144 142 139 135 133 130 113
Total Noncurrent Assets		 79 76 73 65 61 60 62 59 61 60 81
Long-Term Investments		 0.81 0.82 0.84 0.82 0.00 0.00 0.00 - - - 13
Noncurrent Note & Lease Receivables		 6.57 6.69 6.75 6.82 6.94 7.00 7.07 7.19 7.25 7.32 0.00
Other Noncurrent Operating Assets		 52 49 46 39 38 36 39 37 39 38 68
Total Liabilities & Shareholders' Equity		 353 343 291 432 401 444 365 304 402 519 647
Total Liabilities		 782 875 936 843 1,092 1,142 1,109 894 972 1,042 1,516
Total Current Liabilities		 71 565 613 90 54 62 61 49 51 57 68
Accounts Payable		 69 91 89 86 48 56 54 42 43 50 60
Other Current Liabilities		 1.37 2.84 43 4.36 6.08 6.25 7.03 7.46 7.39 7.32 7.63
Total Noncurrent Liabilities		 711 310 323 753 1,038 1,080 1,048 845 921 985 1,448
Long-Term Debt		 661 246 250 645 851 956 973 782 799 817 1,083
Other Noncurrent Operating Liabilities		 50 65 73 107 187 123 75 63 122 168 365
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -429 -532 -645 -411 -691 -697 -744 -590 -570 -523 -869
Total Preferred & Common Equity		 -427 -529 -642 -412 -692 -698 -745 -591 -571 -524 -870
Total Common Equity		 -427 -529 -642 -412 -692 -698 -745 -591 -571 -524 -870
Common Stock		 1,844 1,966 1,991 2,316 2,404 2,532 2,571 2,894 3,014 3,135 3,462
Retained Earnings		 -2,270 -2,495 -2,633 -2,728 -3,096 -3,230 -3,316 -3,505 -3,597 -3,665 -4,359
Accumulated Other Comprehensive Income / (Loss)		 -0.19 -0.03 -0.04 0.79 -0.01 -0.01 0.10 20 13 5.00 27
Noncontrolling Interest		 -2.38 -2.73 -3.07 1.07 1.03 1.01 0.99 0.95 0.93 0.91 0.88

Annual Metrics And Ratios for ImmunityBio

This table displays calculated financial ratios and metrics derived from ImmunityBio's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -63.18% -81.36% 2.27% 4.44% 4,585.11% -72.53% 54.38% -74.30% 159.17% 2,270.58% 668.31%
EBITDA Growth		 -4,437.17% 50.30% 22.61% 3.99% -61.96% -44.22% -53.20% 4.02% -28.01% 41.00% -1.78%
EBIT Growth		 -4,089.17% 48.20% 20.46% 0.82% -59.74% -39.93% -50.45% -2.57% -32.40% 40.37% 8.16%
NOPAT Growth		 -4,184.77% 47.88% 20.39% 0.74% -58.81% -41.36% -49.53% -6.36% -3.12% 4.99% 25.61%
Net Income Growth		 -3,729.85% 49.00% 20.19% 0.20% -66.44% -39.98% -56.05% -19.29% -39.91% 29.15% 15.03%
EPS Growth		 -341.33% 55.59% 18.37% -1.67% 64.75% -37.21% -50.85% -16.85% -10.58% 46.09% 38.71%
Operating Cash Flow Growth		 -348.03% -52.51% -26.40% -29.93% -139.99% -12.90% -59.80% -22.99% -8.67% -6.67% 22.06%
Free Cash Flow Firm Growth		 -8,311.25% 49.12% -35.52% 43.79% -60.44% -13.71% -87.46% -34.49% 61.60% 178.97% 64.39%
Invested Capital Growth		 610.36% 38.06% 424.78% 0.23% 2.08% -42.47% 12.57% 163.70% -114.17% -2,063.88% -45.25%
Revenue Q/Q Growth		 0.00% -2.22% -4.26% -9.62% 5,270.73% -79.28% 135.26% -56.91% 11.87% 101.10% 98.14%
EBITDA Q/Q Growth		 0.00% 5.38% -0.65% 8.71% -139.55% 14.13% -3.60% 6.03% -52.95% 43.58% -36.40%
EBIT Q/Q Growth		 0.00% 3.73% -0.01% 7.02% -126.41% 14.80% -3.83% 2.02% -40.60% 40.11% -28.97%
NOPAT Q/Q Growth		 0.00% 3.70% -0.25% 7.24% -125.10% 14.40% -3.73% -1.63% -0.14% 4.44% -23.05%
Net Income Q/Q Growth		 0.00% 2.09% -0.26% 6.91% -137.31% 15.60% -7.03% -4.19% -27.27% 29.64% -21.95%
EPS Q/Q Growth		 0.00% -7.30% -1.69% 6.87% 44.16% -103.45% -5.95% -2.97% -10.58% 31.87% 5.00%
Operating Cash Flow Q/Q Growth		 -47.03% 0.49% -6.29% -0.62% -151.38% 21.86% -5.39% -5.99% -7.17% 7.15% 4.62%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -17.28% 24.90% -114.94% 26.37% -20.34% 3.77% 31.19% 131.43% -56.61%
Invested Capital Q/Q Growth		 0.00% 2.31% 38.07% 1.05% -1.28% -33.94% 36.15% -3.98% -137.09% -459.85% 66.03%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.34%
EBITDA Margin		 -101,125.00% -269,597.73% -204,000.00% -187,521.28% -6,482.43% -34,026.61% -33,767.02% -126,130.83% -62,299.84% -1,550.63% -205.41%
Operating Margin		 -101,218.64% -282,954.55% -220,266.67% -209,338.30% -7,095.87% -36,509.09% -35,361.88% -146,374.17% -58,239.55% -2,334.23% -226.00%
EBIT Margin		 -101,764.83% -282,754.55% -219,917.78% -208,836.17% -7,120.12% -36,263.47% -35,341.22% -141,072.50% -72,070.10% -1,812.77% -216.69%
Profit (Net Income) Margin		 -100,371.19% -274,565.91% -214,273.33% -204,736.17% -7,273.30% -37,055.70% -37,456.96% -173,883.33% -93,866.88% -2,805.32% -310.25%
Tax Burden Percent		 99.87% 99.53% 99.49% 99.48% 99.93% 99.18% 100.00% 100.01% 99.99% 100.00% 99.96%
Interest Burden Percent		 98.76% 97.56% 97.93% 98.55% 102.22% 103.03% 105.98% 123.25% 130.25% 154.75% 143.23%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -4,565.55% -803.71% -176.60% -104.23% -163.63% -290.68% -559.89% -309.20% -512.32% 0.00% -213.79%
ROIC Less NNEP Spread (ROIC-NNEP)		 -4,532.36% -792.98% -164.13% -80.72% -87.27% -424.22% -613.22% -349.40% -570.54% 0.00% -243.61%
Return on Net Nonoperating Assets (RNNOA)		 4,454.64% 766.50% 138.95% 51.48% 43.52% -20,192.37% 752.96% 429.51% 625.06% 0.00% 284.96%
Return on Equity (ROE)		 -110.91% -37.21% -37.65% -52.75% -120.11% -20,483.05% 193.07% 120.31% 112.74% 77.02% 71.17%
Cash Return on Invested Capital (CROIC)		 -1,955.08% -835.68% -312.58% -104.46% -165.69% -236.77% -571.71% -399.22% 0.00% 0.00% -155.31%
Operating Return on Assets (OROA)		 -112.60% -36.36% -34.85% -45.40% -96.46% -120.38% -95.64% -81.46% -103.43% -60.24% -55.49%
Return on Assets (ROA)		 -111.06% -35.31% -33.96% -44.51% -98.54% -123.01% -101.36% -100.41% -134.71% -93.23% -79.44%
Return on Common Equity (ROCE)		 -110.91% -37.21% -37.65% -52.75% -120.11% -8,150.18% 192.85% 119.58% 112.58% 77.17% 71.30%
Return on Equity Simple (ROE_SIMPLE)		 -66.54% -41.17% -44.06% -65.91% -132.71% 187.12% 144.46% 93.29% 99.47% 84.57% 0.00%
Net Operating Profit after Tax (NOPAT)		 -167 -87 -69 -69 -109 -155 -231 -246 -254 -241 -179
NOPAT Margin		 -70,853.05% -198,068.18% -154,186.67% -146,536.81% -4,967.11% -25,556.36% -24,753.32% -102,461.92% -40,767.68% -1,633.96% -158.20%
Net Nonoperating Expense Percent (NNEP)		 -33.19% -10.72% -12.47% -23.51% -76.36% 133.54% 53.33% 40.20% 58.21% 49.05% 29.82%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -110.10% -101.02% 118.26% -59.32%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.66%
SG&A Expenses to Revenue		 96,473.73% 216,797.73% 126,935.56% 90,889.36% 2,109.72% 11,788.10% 14,481.37% 42,795.00% 20,839.23% 1,144.68% 132.41%
R&D to Revenue		 4,844.92% 66,256.82% 93,431.11% 118,548.94% 5,086.15% 23,059.01% 20,980.51% 103,395.42% 37,357.88% 1,289.55% 192.92%
Operating Expenses to Revenue		 101,318.64% 283,054.55% 220,366.67% 209,438.30% 7,195.87% 36,609.09% 35,461.88% 146,474.17% 58,339.55% 2,434.23% 325.33%
Earnings before Interest and Taxes (EBIT)		 -240 -124 -99 -98 -157 -219 -330 -339 -448 -267 -245
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -239 -119 -92 -88 -143 -206 -315 -303 -388 -229 -233
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.95 1.61 1.63 0.63 3.09 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 4.04 1.63 1.65 0.63 3.09 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 5,964.19 10,708.81 7,927.86 1,955.37 169.31 2,392.63 2,588.20 8,456.42 5,388.88 120.98 17.21
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 116.43 15.13 3.09 0.18 4.73 41.34 61.81 22.48 0.00 0.00 42.32
Enterprise Value to Revenue (EV/Rev)		 4,494.34 4,326.06 4,531.35 256.43 145.17 2,654.87 2,894.31 10,800.82 6,306.32 130.18 22.16
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 19.94 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.01 0.02 0.02 0.00 0.00 -2.15 -2.48 -1.50 -1.43 -0.58 -1.60
Long-Term Debt to Equity		 0.01 0.02 0.02 0.00 0.00 -2.15 -1.26 -0.54 -1.43 -0.58 -1.60
Financial Leverage		 -0.98 -0.97 -0.85 -0.64 -0.50 47.60 -1.23 -1.23 -1.10 -0.66 -1.17
Leverage Ratio		 1.00 1.05 1.11 1.19 1.22 166.52 -1.90 -1.20 -0.84 -0.83 -0.90
Compound Leverage Factor		 0.99 1.03 1.09 1.17 1.25 171.56 -2.02 -1.48 -1.09 -1.28 -1.28
Debt to Total Capital		 0.69% 1.89% 2.19% 0.00% 0.00% 187.21% 167.44% 301.40% 333.43% -139.60% 265.35%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 82.74% 193.37% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.69% 1.89% 2.19% 0.00% 0.00% 187.21% 84.70% 108.02% 333.43% -139.60% 265.35%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.97% -0.48% -1.12% 0.42% -0.48% 0.30%
Common Equity to Total Capital		 99.31% 98.11% 97.81% 100.00% 100.00% -88.18% -66.96% -200.28% -233.85% 240.08% -165.64%
Debt to EBITDA		 -0.01 -0.05 -0.05 0.00 0.00 -1.24 -1.92 -2.22 -2.16 -1.24 -3.45
Net Debt to EBITDA		 1.45 2.37 1.67 0.00 0.00 -0.76 -0.91 -1.87 -1.47 -0.59 -2.40
Long-Term Debt to EBITDA		 -0.01 -0.05 -0.05 0.00 0.00 -1.24 -0.97 -0.80 -2.16 -1.24 -3.45
Debt to NOPAT		 -0.01 -0.06 -0.07 0.00 0.00 -1.65 -2.62 -2.74 -3.30 -1.18 -4.47
Net Debt to NOPAT		 2.07 3.22 2.20 0.00 0.00 -1.02 -1.24 -2.30 -2.25 -0.56 -3.12
Long-Term Debt to NOPAT		 -0.01 -0.06 -0.07 0.00 0.00 -1.65 -1.33 -0.98 -3.30 -1.18 -4.47
Altman Z-Score		 75.65 9.47 3.22 -4.42 0.26 -10.69 -6.23 -11.97 -8.75 -12.97 -10.01
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 60.21% 0.12% 0.61% 0.14% -0.19% -0.19%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 48.40 16.34 6.35 3.26 4.82 1.64 0.91 0.28 5.05 3.36 5.10
Quick Ratio		 47.89 15.93 6.15 2.75 4.47 1.44 0.86 0.22 4.61 2.77 4.62
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -178 -91 -123 -69 -111 -126 -236 -318 -122 96 -130
Operating Cash Flow to CapEx		 -1,129.18% -588.31% -140.11% -499.46% -3,721.78% -10,289.04% -2,100.41% -431.81% -1,199.18% -5,679.97% -7,171.59%
Free Cash Flow to Firm to Interest Expense		 0.00 -1,372.98 -198.72 -159.42 -18.71 -13.88 -15.90 -5.00 -0.94 0.62 -1.16
Operating Cash Flow to Interest Expense		 0.00 -584.74 -78.93 -146.38 -25.69 -18.92 -18.48 -5.31 -2.84 -2.54 -2.71
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -684.14 -135.27 -175.68 -26.38 -19.11 -19.36 -6.54 -3.08 -2.58 -2.75
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.01 0.00 0.00 0.00 0.00 0.03 0.26
Accounts Receivable Turnover		 0.00 0.07 0.07 0.00 0.00 0.00 0.56 0.15 0.32 6.31 5.01
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16
Fixed Asset Turnover		 0.08 0.00 0.00 0.00 0.03 0.01 0.01 0.00 0.00 0.10 0.90
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01
Days Sales Outstanding (DSO)		 0.00 5,416.93 5,041.06 0.00 0.00 0.00 651.84 2,450.82 1,146.93 57.83 72.93
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2,225.39
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 24,647.68
Cash Conversion Cycle (CCC)		 0.00 5,416.93 5,041.06 0.00 0.00 0.00 651.84 2,450.82 1,146.93 57.83 -22,349.37
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 9.11 13 66 66 68 39 44 115 -16 -354 59
Invested Capital Turnover		 0.06 0.00 0.00 0.00 0.03 0.01 0.02 0.00 0.01 -0.08 1.35
Increase / (Decrease) in Invested Capital		 11 3.47 53 0.16 1.37 -29 4.88 72 -132 -337 -49
Enterprise Value (EV)		 1,061 190 204 12 320 1,606 2,703 2,592 3,923 1,919 2,510
Market Capitalization		 1,408 471 357 92 373 1,448 2,417 2,030 3,352 1,784 1,950
Book Value per Share		 $4.38 $3.56 $2.75 $1.84 $1.23 ($1.10) ($0.61) ($1.12) ($0.88) ($0.70) ($0.51)
Tangible Book Value per Share		 $4.29 $3.50 $2.72 $1.84 $1.23 ($1.12) ($0.61) ($1.17) ($0.90) ($0.72) ($0.52)
Total Capital		 358 299 224 146 121 136 362 223 251 -204 302
Total Debt		 2.47 5.65 4.91 0.00 0.00 254 606 673 837 284 802
Total Long-Term Debt		 2.47 5.65 4.91 0.00 0.00 254 306 241 837 284 802
Net Debt		 -347 -281 -153 -80 -53 157 288 565 570 135 559
Capital Expenditures (CapEx)		 2.24 6.56 35 13 4.09 1.67 13 78 31 6.89 4.25
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.83 -6.33 -17 -13 -7.45 -52 -53 -36 -31 -20 10
Debt-free Net Working Capital (DFNWC)		 291 193 112 62 44 44 265 72 236 130 253
Net Working Capital (NWC)		 291 193 112 62 44 44 -35 -360 236 130 253
Net Nonoperating Expense (NNE)		 70 34 27 27 51 70 119 171 330 173 172
Net Nonoperating Obligations (NNO)		 -347 -281 -153 -80 -53 157 288 565 570 135 559
Total Depreciation and Amortization (D&A)		 1.51 5.79 7.16 10 14 14 15 36 61 39 13
Debt-free, Cash-free Net Working Capital to Revenue		 -1,197.46% -14,384.09% -36,804.44% -26,887.23% -338.51% -8,674.71% -5,623.98% -14,819.58% -4,929.42% -136.77% 9.09%
Debt-free Net Working Capital to Revenue		 123,471.19% 437,709.09% 247,977.78% 130,876.60% 2,007.18% 7,203.14% 28,328.48% 29,840.42% 37,910.13% 879.23% 223.43%
Net Working Capital to Revenue		 123,471.19% 437,709.09% 247,977.78% 130,876.60% 2,007.18% 7,203.14% -3,709.64% -150,118.33% 37,910.13% 879.23% 223.43%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.31) ($1.47) ($1.20) ($1.22) ($0.70) ($0.89) ($0.89) ($1.04) ($1.15) ($0.59) ($0.38)
Adjusted Weighted Average Basic Shares Outstanding		 81.93M 82.30M 79.03M 79.09M 98.48M 109.34M 389.23M 399.90M 508.64M 697.31M 919.86M
Adjusted Diluted Earnings per Share		 ($3.31) ($1.47) ($1.20) ($1.22) ($0.70) ($0.89) ($0.89) ($1.04) ($1.15) ($0.62) ($0.38)
Adjusted Weighted Average Diluted Shares Outstanding		 81.93M 82.30M 79.03M 79.09M 98.48M 109.34M 389.23M 399.90M 508.64M 700.44M 919.86M
Adjusted Basic & Diluted Earnings per Share		 ($3.31) ($1.47) ($1.20) ($1.22) ($0.70) ($0.89) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 71.52M 81.98M 80.58M 79.13M 94.21M 103.55M 397.91M 435.84M 673.95M 853.44M 1.03B
Normalized Net Operating Profit after Tax (NOPAT)		 -167 -87 -69 -69 -109 -147 -231 -245 -253 -241 -179
Normalized NOPAT Margin		 -70,853.05% -198,068.18% -154,186.67% -146,536.81% -4,967.11% -24,322.98% -24,753.32% -102,263.29% -40,667.97% -1,633.96% -158.20%
Pre Tax Income Margin		 -100,498.73% -275,865.91% -215,368.89% -205,806.38% -7,278.07% -37,360.83% -37,456.00% -173,869.17% -93,873.31% -2,805.32% -310.37%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -1,885.03 -160.13 -226.68 -26.48 -24.18 -22.23 -5.33 -3.47 -1.73 -2.18
NOPAT to Interest Expense		 0.00 -1,320.45 -112.27 -159.06 -18.48 -17.04 -15.57 -3.87 -1.96 -1.56 -1.59
EBIT Less CapEx to Interest Expense		 0.00 -1,984.42 -216.47 -255.99 -27.17 -24.36 -23.11 -6.56 -3.71 -1.78 -2.22
NOPAT Less CapEx to Interest Expense		 0.00 -1,419.85 -168.61 -188.37 -19.17 -17.22 -16.45 -5.10 -2.20 -1.61 -1.63
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -2.03% -13.12% -15.79% -0.24% -1.56% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for ImmunityBio

This table displays calculated financial ratios and metrics derived from ImmunityBio's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 1,028,111,456.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 1,028,111,456.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - -0.62
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -30.51% 90.41% -88.89% 2,453.66% 7,346.34% 5,333.09% 41,192.50% 0.00% 425.07% 652.53% 167.64%
EBITDA Growth		 46.96% -239.15% -30.84% -3.09% 14.18% 92.81% -8.89% 32.31% 7.40% -47.37% -515.20%
EBIT Growth		 34.58% -178.89% -17.20% 4.42% 20.37% 88.71% -2.19% 33.74% 14.12% -45.21% -495.20%
NOPAT Growth		 11.75% -0.58% 14.68% -16.66% -0.15% 18.72% 32.32% 28.24% 30.68% -43.29% -8.32%
Net Income Growth		 13.96% -115.47% -15.05% 2.63% 10.34% 74.65% 3.33% 31.21% 21.55% -39.26% -388.02%
EPS Growth		 32.14% -42.31% 25.93% 37.50% 26.32% 78.38% 25.00% 50.00% 50.00% 25.00% -313.33%
Operating Cash Flow Growth		 -8.44% -27.05% -26.89% -25.79% -13.00% 26.14% 19.70% 20.53% 30.23% 17.34% 12.28%
Free Cash Flow Firm Growth		 113.17% 154.87% 140.43% -1,080.82% -653.00% 301.45% -594.01% 3.86% 90.78% 869.35% 240.47%
Invested Capital Growth		 -63.32% -114.17% -111.76% 2.21% 123.03% -2,063.88% 1,283.77% 84.96% -63.64% -45.25% -238.69%
Revenue Q/Q Growth		 100.00% 69.51% -71.22% 2,517.50% 483.19% 23.68% 118.71% -100.00% 0.00% 101.83% -31.69%
EBITDA Q/Q Growth		 48.96% -338.59% 52.63% 2.79% 57.51% 63.28% -617.91% -27.65% 37.52% 188.14% -975.18%
EBIT Q/Q Growth		 41.74% -239.75% 50.58% 2.29% 51.46% 51.82% -347.18% -26.71% 37.09% 182.26% -1,007.75%
NOPAT Q/Q Growth		 5.88% -6.56% -11.49% -4.35% 19.21% 13.52% 7.16% -121.28% 21.96% 180.24% -178.18%
Net Income Q/Q Growth		 30.80% -144.05% 42.54% -0.34% 36.28% 30.99% -119.11% -42.79% 27.33% 172.75% -746.44%
EPS Q/Q Growth		 40.63% -94.74% 45.95% 0.00% 30.00% 42.86% -87.50% 33.33% 30.00% 14.29% -933.33%
Operating Cash Flow Q/Q Growth		 -9.56% -31.88% 7.19% 6.20% 1.58% 13.79% -0.89% 7.17% 13.59% -2.13% -7.08%
Free Cash Flow Firm Q/Q Growth		 178.00% 260.21% -47.63% -287.02% -56.74% 361.49% -164.45% 27.66% 88.58% 825.93% 134.30%
Invested Capital Q/Q Growth		 10.08% -137.09% 32.82% 472.66% 140.19% -459.85% 136.75% -41.77% -52.78% 66.03% -403.81%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 99.65% 0.00% 98.90% 99.89% 99.46%
EBITDA Margin		 -52,900.00% -136,871.22% -225,322.50% -8,367.91% -609.71% -181.02% -594.21% 0.00% -244.14% 106.61% -1,365.84%
Operating Margin		 -97,726.83% -61,430.94% -237,990.00% -9,487.39% -1,314.33% -918.96% -390.08% 0.00% -347.03% 96.17% -157.88%
EBIT Margin		 -72,440.24% -145,188.49% -249,355.00% -9,308.12% -774.70% -301.80% -617.07% 0.00% -253.41% 103.27% -1,372.30%
Profit (Net Income) Margin		 -116,636.59% -167,923.74% -335,325.00% -12,854.25% -1,404.39% -783.62% -785.05% 0.00% -419.66% 151.27% -1,431.47%
Tax Burden Percent		 100.00% 99.98% 100.00% 100.00% 100.00% 100.00% 99.82% 100.29% 99.95% 100.38% 100.00%
Interest Burden Percent		 161.01% 115.68% 134.48% 138.10% 181.28% 259.65% 127.45% 142.94% 165.69% 145.93% 104.31%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -0.41% 0.00%
Return on Invested Capital (ROIC)		 -463.40% -540.40% -1,222.06% -214.69% -94.81% 0.00% -143.34% 0.00% -207.35% 130.50% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -471.28% -571.00% -1,232.41% -223.83% -99.37% 0.00% -155.41% 0.00% -215.43% 136.63% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 563.41% 625.58% 1,315.40% 237.33% 111.62% 0.00% 169.84% 0.00% 238.20% -159.83% 0.00%
Return on Equity (ROE)		 100.01% 85.18% 93.34% 22.63% 16.80% 77.02% 26.50% 0.00% 30.86% -29.32% 117.10%
Cash Return on Invested Capital (CROIC)		 -215.87% 0.00% 0.00% -625.11% -430.53% 0.00% -277.30% -368.70% -124.10% -155.31% 0.00%
Operating Return on Assets (OROA)		 -102.57% -208.37% -202.41% -33.10% -14.25% -10.03% -54.70% 0.00% -32.80% 26.45% -407.12%
Return on Assets (ROA)		 -165.15% -241.00% -272.20% -45.72% -25.84% -26.04% -69.59% 0.00% -54.31% 38.74% -424.68%
Return on Common Equity (ROCE)		 99.85% 85.06% 93.21% 22.60% 16.83% 77.17% 26.54% 0.00% 30.90% -29.38% 117.25%
Return on Equity Simple (ROE_SIMPLE)		 111.43% 0.00% 86.91% 85.59% 78.89% 0.00% 69.18% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -56 -60 -67 -70 -56 -49 -45 -100 -78 62 -49
NOPAT Margin		 -68,408.78% -43,001.65% -166,593.00% -6,641.17% -920.03% -643.27% -273.05% 0.00% -242.92% 96.57% -110.51%
Net Nonoperating Expense Percent (NNEP)		 7.88% 30.60% 10.34% 9.14% 4.56% 3.01% 12.08% 12.34% 8.09% -6.13% 82.87%
Return On Investment Capital (ROIC_SIMPLE)		 - -23.81% - - - 23.85% -23.55% -43.52% -26.53% 20.68% -22.88%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.35% 0.00% 1.10% 0.11% 0.54%
SG&A Expenses to Revenue		 38,800.00% 23,820.14% 104,712.50% 4,704.01% 588.21% 552.58% 197.70% 0.00% 226.33% -61.65% 103.54%
R&D to Revenue		 59,026.83% 37,073.38% 133,377.50% 4,883.38% 826.12% 466.38% 292.03% 0.00% 319.59% -65.85% 153.80%
Operating Expenses to Revenue		 97,826.83% 61,530.94% 238,090.00% 9,587.39% 1,414.33% 1,018.96% 489.73% 0.00% 545.92% -127.50% 257.34%
Earnings before Interest and Taxes (EBIT)		 -59 -202 -100 -97 -47 -23 -102 -129 -81 67 -607
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -43 -190 -90 -88 -37 -14 -98 -125 -78 69 -604
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Revenue (P/Rev)		 1,386.80 5,388.88 11,983.85 3,341.52 353.40 120.98 82.28 74.63 40.67 17.21 55.94
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 27.85 0.00 0.00 124.93 34.96 0.00 25.32 39.34 80.76 42.32 0.00
Enterprise Value to Revenue (EV/Rev)		 2,206.52 6,306.32 14,238.94 3,906.73 468.43 130.18 105.38 95.33 50.46 22.16 60.83
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 19.94 0.00 0.00 0.00 0.00 67.44
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -1.57 -1.43 -1.23 -1.37 -1.31 -0.58 -1.32 -1.40 -1.56 -1.60 -1.25
Long-Term Debt to Equity		 -1.57 -1.43 -1.23 -1.37 -1.31 -0.58 -1.32 -1.40 -1.56 -1.60 -1.25
Financial Leverage		 -1.20 -1.10 -1.07 -1.06 -1.12 -0.66 -1.09 -1.09 -1.11 -1.17 -0.97
Leverage Ratio		 -0.94 -0.84 -0.61 -0.55 -0.69 -0.83 -0.55 -0.67 -0.70 -0.90 -0.65
Compound Leverage Factor		 -1.51 -0.97 -0.82 -0.76 -1.25 -2.15 -0.70 -0.95 -1.15 -1.31 -0.68
Debt to Total Capital		 274.99% 333.43% 533.17% 369.38% 425.51% -139.60% 408.31% 348.49% 278.31% 265.35% 506.97%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 274.99% 333.43% 533.17% 369.38% 425.51% -139.60% 408.31% 348.49% 278.31% 265.35% 506.97%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.46% 0.42% 0.65% 0.39% 0.43% -0.48% 0.50% 0.41% 0.31% 0.30% 0.41%
Common Equity to Total Capital		 -175.45% -233.85% -433.81% -269.77% -325.94% 240.08% -308.81% -248.89% -178.62% -165.64% -407.38%
Debt to EBITDA		 -2.55 -2.16 -2.08 -2.32 -2.40 -1.24 -3.30 -4.52 -4.79 -3.45 -1.47
Net Debt to EBITDA		 -1.79 -1.47 -1.66 -1.79 -2.08 -0.59 -3.04 -3.65 -3.28 -2.40 -0.93
Long-Term Debt to EBITDA		 -2.55 -2.16 -2.08 -2.32 -2.40 -1.24 -3.30 -4.52 -4.79 -3.45 -1.47
Debt to NOPAT		 -2.55 -3.30 -3.51 -3.79 -3.86 -1.18 -3.56 -4.44 -5.61 -4.47 -5.92
Net Debt to NOPAT		 -1.80 -2.25 -2.81 -2.93 -3.34 -0.56 -3.28 -3.58 -3.84 -3.12 -3.77
Long-Term Debt to NOPAT		 -2.55 -3.30 -3.51 -3.79 -3.86 -1.18 -3.56 -4.44 -5.61 -4.47 -5.92
Altman Z-Score		 -8.39 -7.13 -9.22 -8.11 -11.40 -10.86 -15.20 -11.60 -8.32 -7.96 -8.48
Noncontrolling Interest Sharing Ratio		 0.16% 0.14% 0.14% 0.15% -0.18% -0.19% -0.15% 0.00% -0.15% -0.19% -0.13%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.38 5.05 3.64 3.91 2.68 3.36 2.22 4.11 5.77 5.10 6.67
Quick Ratio		 2.13 4.61 3.21 3.54 2.22 2.77 1.61 3.48 5.07 4.62 6.24
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 20 72 38 -70 -110 289 -186 -135 -15 112 261
Operating Cash Flow to CapEx		 -1,540.14% -1,449.04% -8,483.90% -13,860.08% -3,537.36% -4,033.35% -7,663.25% -7,377.06% -9,299.19% -5,376.47% -4,217.07%
Free Cash Flow to Firm to Interest Expense		 0.57 2.24 1.00 -1.80 -2.74 7.68 -6.44 -4.35 -0.28 0.00 9.18
Operating Cash Flow to Interest Expense		 -2.50 -3.59 -2.85 -2.57 -2.45 -2.27 -2.98 -2.58 -1.25 0.00 -2.65
Operating Cash Flow Less CapEx to Interest Expense		 -2.66 -3.84 -2.89 -2.59 -2.52 -2.32 -3.01 -2.61 -1.26 0.00 -2.71
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.02 0.03 0.09 0.07 0.13 0.26 0.30
Accounts Receivable Turnover		 0.29 0.32 0.17 0.64 2.03 6.31 3.19 2.56 3.10 5.01 4.64
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.16 0.16 0.21
Fixed Asset Turnover		 0.00 0.00 0.00 0.01 0.05 0.10 0.22 0.23 0.43 0.90 1.14
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.02
Days Sales Outstanding (DSO)		 1,251.57 1,146.93 2,176.10 569.96 179.94 57.83 114.51 142.57 117.90 72.93 78.61
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4,673.66 2,310.87 2,225.39 1,758.69
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 281,370.95 54,812.49 27,680.50 24,647.68 19,965.66
Cash Conversion Cycle (CCC)		 1,251.57 1,146.93 2,176.10 569.96 179.94 57.83 -281,256.44 -49,996.27 -25,251.73 -22,349.37 -18,128.35
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 44 -16 -11 41 98 -354 130 76 36 59 -180
Invested Capital Turnover		 0.01 0.01 0.01 0.03 0.10 -0.08 0.52 0.54 0.85 1.35 -5.61
Increase / (Decrease) in Invested Capital		 -76 -132 -104 0.89 54 -337 141 35 -63 -49 -310
Enterprise Value (EV)		 1,227 3,923 4,300 5,110 3,434 1,919 3,290 2,977 2,885 2,510 8,575
Market Capitalization		 771 3,352 3,619 4,371 2,591 1,784 2,569 2,330 2,325 1,950 7,886
Book Value per Share		 ($0.90) ($0.88) ($1.03) ($1.01) ($1.07) ($0.70) ($0.69) ($0.65) ($0.55) ($0.51) ($0.85)
Tangible Book Value per Share		 ($0.94) ($0.90) ($1.05) ($1.03) ($1.09) ($0.72) ($0.71) ($0.66) ($0.57) ($0.52) ($0.85)
Total Capital		 235 251 160 259 229 -204 192 229 294 302 214
Total Debt		 645 837 851 956 973 284 782 799 817 802 1,083
Total Long-Term Debt		 645 837 851 956 973 284 782 799 817 802 1,083
Net Debt		 455 570 680 738 842 135 720 645 559 559 689
Capital Expenditures (CapEx)		 5.68 7.96 1.26 0.72 2.79 2.11 1.12 1.08 0.74 1.31 1.79
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -65 -31 -29 -37 -28 -20 -1.63 3.83 15 10 4.12
Debt-free Net Working Capital (DFNWC)		 125 236 142 181 102 130 60 157 272 253 385
Net Working Capital (NWC)		 125 236 142 181 102 130 60 157 272 253 385
Net Nonoperating Expense (NNE)		 40 174 67 65 30 11 85 85 57 -35 584
Net Nonoperating Obligations (NNO)		 455 570 680 738 842 135 720 645 559 559 689
Total Depreciation and Amortization (D&A)		 16 12 9.61 9.84 10 9.12 3.78 3.87 2.97 2.16 2.85
Debt-free, Cash-free Net Working Capital to Revenue		 -11,697.48% -4,929.42% -9,447.68% -2,848.55% -384.30% -136.77% -5.23% 12.27% 25.45% 9.09% 2.92%
Debt-free Net Working Capital to Revenue		 22,438.49% 37,910.13% 47,007.62% 13,816.51% 1,393.75% 879.23% 192.04% 504.41% 476.35% 223.43% 273.09%
Net Working Capital to Revenue		 22,438.49% 37,910.13% 47,007.62% 13,816.51% 1,393.75% 879.23% 192.04% 504.41% 476.35% 223.43% 273.09%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.19) ($0.37) ($0.20) ($0.20) ($0.12) ($0.07) ($0.15) ($0.10) ($0.07) ($0.06) ($0.62)
Adjusted Weighted Average Basic Shares Outstanding		 498.38M 508.64M 672.83M 686.94M 695.90M 697.31M 853.16M 888.22M 946.60M 919.86M 1.03B
Adjusted Diluted Earnings per Share		 ($0.19) ($0.37) ($0.20) ($0.20) ($0.14) ($0.08) ($0.15) ($0.10) ($0.07) ($0.06) ($0.62)
Adjusted Weighted Average Diluted Shares Outstanding		 498.38M 508.64M 672.83M 686.94M 697.96M 700.44M 853.16M 888.22M 946.60M 919.86M 1.03B
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 667.71M 673.95M 691.57M 696.53M 696.83M 853.44M 882.62M 945.25M 984.97M 1.03B 1.05B
Normalized Net Operating Profit after Tax (NOPAT)		 -56 -60 -67 -70 -56 -49 -45 -100 -78 44 -49
Normalized NOPAT Margin		 -68,408.78% -43,001.65% -166,593.00% -6,641.17% -920.03% -643.27% -273.05% 0.00% -242.92% 67.32% -110.51%
Pre Tax Income Margin		 -116,636.59% -167,952.52% -335,325.00% -12,854.25% -1,404.39% -783.62% -786.46% 0.00% -419.88% 150.70% -1,431.45%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -1.70 -6.28 -2.66 -2.50 -1.18 -0.61 -3.53 -4.17 -1.47 0.00 -21.31
NOPAT to Interest Expense		 -1.60 -1.86 -1.78 -1.78 -1.40 -1.29 -1.56 -3.22 -1.41 0.00 -1.72
EBIT Less CapEx to Interest Expense		 -1.86 -6.53 -2.69 -2.52 -1.24 -0.66 -3.57 -4.21 -1.49 0.00 -21.38
NOPAT Less CapEx to Interest Expense		 -1.76 -2.11 -1.81 -1.80 -1.47 -1.35 -1.60 -3.26 -1.43 0.00 -1.78
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

ImmunityBio, Inc. (IBRX) delivered a notable Q4 2025 top-line expansion and a rare quarterly profit, but the company also continues to operate with a substantial cash burn and a heavy balance-sheet burden. Below are the 10 most important takeaways from ImmunityBio’s recent four-year quarterly data, focused on what could matter for retail investors.

  • Q4 2025 revenue rose to $64.71 million with a gross profit of $64.64 million, implying a very high gross margin for the quarter.
  • Q4 2025 operating income turned positive at $62.23 million, signaling a potential profitability inflection on a quarterly basis.
  • Q4 2025 net cash from continuing investing activities was $43.54 million, driven by investment sales and related activity (sale/maturity of investments and partial purchases).
  • Q4 2025 issuance of common equity totaled $53.74 million, providing additional liquidity.
  • Q4 2025 net cash from financing activities was $54.89 million, contributing to cash balances and liquidity runway.
  • Total assets increased to roughly $519 million by late 2025, reflecting balance sheet expansion from year-to-year activity.
  • Total equity remained negative but the deficit narrowed in 2025 (e.g., the equity deficit around the mid-$500 million range by late 2025), indicating a modest improvement in the company’s deficit position.
  • Q4 2025 net change in cash and equivalents was an increase of about $28.09 million, signaling better near-term liquidity for the quarter.
  • Cash balances were around $60 million in late 2025, suggesting a modest liquidity cushion for near-term operating needs.
  • The large Q4 2025 net income figure appears driven by one-time or non-operating items (e.g., tax effects), so the quarterly profit may not be sustainable without ongoing operating improvements.
05/14/26 03:08 PM ETAI Generated. May Contain Errors.

ImmunityBio Financials - Frequently Asked Questions

According to the most recent income statement we have on file, ImmunityBio's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

ImmunityBio's net income appears to be on an upward trend, with a most recent value of -$351.47 million in 2025, rising from -$236.88 million in 2015. The previous period was -$413.65 million in 2024. Find out what analysts predict for ImmunityBio in the coming months.

ImmunityBio's total operating income in 2025 was -$256.03 million, based on the following breakdown:
  • Total Gross Profit: $112.54 million
  • Total Operating Expenses: $368.56 million

Over the last 10 years, ImmunityBio's total revenue changed from $236 thousand in 2015 to $113.29 million in 2025, a change of 47,903.4%.

ImmunityBio's total liabilities were at $1.00 billion at the end of 2025, a 15.0% increase from 2024, and a 9,126.8% increase since 2015.

In the past 10 years, ImmunityBio's cash and equivalents has ranged from $8.08 million in 2016 to $265.45 million in 2023, and is currently $88.33 million as of their latest financial filing in 2025.

Over the last 10 years, ImmunityBio's book value per share changed from 4.38 in 2015 to -0.51 in 2025, a change of -111.6%.


Related Companies

Financial statements for NASDAQ:IBRX last updated on 5/8/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Before you buy SpaceX shares, consider this alternative approach
SpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...
Weiss Ratings | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
NNVC FDA = New Momentum Wave!
NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for its antiviral NV-387, targeting measl...
Equiscreen | Sponsoredtc pixel
Peptide Company Lands Exclusive MMA Wellness Partnership
A publicly traded peptide company just signed an exclusive partnership with a NYSE-listed MMA media platform t...
The Tomorrow Investor | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
The system holding the dollar together is gone…
Saudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...
Golden Portfolio | Sponsoredtc pixel
Millionaire warns: Move your money before May 15
Larry Benedict - the trader who generated $274 million in client profits and beat the S&P 500 by 18 times in 2...
Brownstone Research | Sponsoredtc pixel